The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase
worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease …

Biologicals have dominated the therapeutic scenery in inflammatory bowel diseases (IBDs),
namely ulcerative colitis (UC) and Crohn's disease (CD), for the past 20 years. The …

Background Intravenous [IV] infliximab is a well-established therapy for inflammatory bowel
diseases [IBD] patients. A subcutaneous [SC] formulation of infliximab [CT-P13] has recently …

Over the past two decades, 11 biologic agents have been approved for use in most
countries for the treatment of moderate-to-severe inflammatory bowel disease (IBD) …

Background Onset of effect of advanced therapies is an important parameter due to
symptom load and risk of disease complications in moderate-to-severe ulcerative colitis …

Background Thiopurines remain recommended as maintenance therapy in patients with
inflammatory bowel disease (IBD). Despite their widespread use, long‐term effectiveness …

Abstract Background and Aims This study compares the effectiveness of different biologic
therapies and sequences in patients with inflammatory bowel disease [IBD] using real-world …

Abstract Background Inflammatory bowel diseases (IBDs) are associated with high
healthcare utilization. This systematic review aimed to summarize what is known about the …

Objectives Pneumocystis pneumonia (PCP) is an opportunistic infection that causes
significant morbidity and mortality in the immunocompromised population. This population is …

Abstract Background and Aims Few studies have assessed the contemporary patterns of
disease activity in patients with inflammatory bowel disease [IBD]. We aimed to describe the …